File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-49649115869
- PMID: 18713499
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis
Title | Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis |
---|---|
Authors | |
Keywords | Costs and cost analysis Developing countries Diagnostic techniques and procedures Point-of-care systems Tuberculosis |
Issue Date | 2008 |
Citation | International Journal of Tuberculosis and Lung Disease, 2008, v. 12, n. 9, p. 1021-1029 How to Cite? |
Abstract | SETTING: The potential cost-effectiveness of improved diagnostic tests for tuberculosis (TB) in resource-limited settings is unknown. OBJECTIVE: To estimate the incremental cost-effectiveness of a hypothetical new point-of-care TB diagnostic test in South Africa, Brazil and Kenya. DESIGN: Decision-analysis model, adding four diagnostic interventions (sputum smear microscopy, new test, smear plus new test and smear plus TB culture) to a baseline of existing infrastructure without smear. RESULTS: Adding sputum smear was estimated to be more cost-effective (incremental cost per disability-adjusted life year [DALY] of $86 [South Africa], $131 [Brazil], $38 (Kenya]) than a new TB diagnostic with 70% sensitivity, 95% specificity and price of $20 per test ($198 [South Africa], $275 [Brazil], $84 [Kenya]). However, compared to sputum smear, smear plus new test averted 46-49% more DALYs per 1000 TB suspects (321 vs. 215 [South Africa], 243 vs. 166 [Brazil], 790 vs. 531 [Kenya]), at an incremental cost of $170 (Kenya) to $625 (Brazil) per DALY averted. Cost-effectiveness was most sensitive to the specificity and price of the new test, the baseline TB case detection rate and the discount rate. CONCLUSION: Novel diagnostic tests for TB are potentially highly cost-effective. Cost-effectiveness is maximized by high-specificity, low-cost tests deployed to regions with poor infrastructure. |
Persistent Identifier | http://hdl.handle.net/10722/326749 |
ISSN | 2023 Impact Factor: 3.4 2023 SCImago Journal Rankings: 0.952 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dowdy, D. W. | - |
dc.contributor.author | O'Brien, M. A. | - |
dc.contributor.author | Bishai, D. | - |
dc.date.accessioned | 2023-03-31T05:26:15Z | - |
dc.date.available | 2023-03-31T05:26:15Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | International Journal of Tuberculosis and Lung Disease, 2008, v. 12, n. 9, p. 1021-1029 | - |
dc.identifier.issn | 1027-3719 | - |
dc.identifier.uri | http://hdl.handle.net/10722/326749 | - |
dc.description.abstract | SETTING: The potential cost-effectiveness of improved diagnostic tests for tuberculosis (TB) in resource-limited settings is unknown. OBJECTIVE: To estimate the incremental cost-effectiveness of a hypothetical new point-of-care TB diagnostic test in South Africa, Brazil and Kenya. DESIGN: Decision-analysis model, adding four diagnostic interventions (sputum smear microscopy, new test, smear plus new test and smear plus TB culture) to a baseline of existing infrastructure without smear. RESULTS: Adding sputum smear was estimated to be more cost-effective (incremental cost per disability-adjusted life year [DALY] of $86 [South Africa], $131 [Brazil], $38 (Kenya]) than a new TB diagnostic with 70% sensitivity, 95% specificity and price of $20 per test ($198 [South Africa], $275 [Brazil], $84 [Kenya]). However, compared to sputum smear, smear plus new test averted 46-49% more DALYs per 1000 TB suspects (321 vs. 215 [South Africa], 243 vs. 166 [Brazil], 790 vs. 531 [Kenya]), at an incremental cost of $170 (Kenya) to $625 (Brazil) per DALY averted. Cost-effectiveness was most sensitive to the specificity and price of the new test, the baseline TB case detection rate and the discount rate. CONCLUSION: Novel diagnostic tests for TB are potentially highly cost-effective. Cost-effectiveness is maximized by high-specificity, low-cost tests deployed to regions with poor infrastructure. | - |
dc.language | eng | - |
dc.relation.ispartof | International Journal of Tuberculosis and Lung Disease | - |
dc.subject | Costs and cost analysis | - |
dc.subject | Developing countries | - |
dc.subject | Diagnostic techniques and procedures | - |
dc.subject | Point-of-care systems | - |
dc.subject | Tuberculosis | - |
dc.title | Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.pmid | 18713499 | - |
dc.identifier.scopus | eid_2-s2.0-49649115869 | - |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | 1021 | - |
dc.identifier.epage | 1029 | - |
dc.identifier.f1000 | 1120900 | - |